Skip to content

Hyaluronan Versus NaCl 20 Ml Versus Placebo in Knee Osteoarthritis

Intra-Articular Injections of Hyaluronan Versus 20 Ml NaCl Versus Placebo in Treatment of Knee Osteoarthritis: a Randomised, Double-Blind, Placebo Controlled Single Centre Trial.

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00144820
Enrollment
251
Registered
2005-09-05
Start date
1999-05-31
Completion date
2001-11-30
Last updated
2005-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis, Knee

Keywords

Hyaluronan, Gonarthrosis, Osteoarthritis,knee, Double-blinded, Placebo controlled, Randomised

Brief summary

251 consecutive patients with knee arthrosis were randomized to one of three interventions: Four weekly injections of 2 ml isotonic saline (placebo), 2 ml sodium hyaluronate (hyaluronan) or 20 ml isotonic saline (excessive saline). They all suffered from clinically and radiologically verified arthrosis of the knee with daily pain that did not respond to treatment with analgetics. Results were evaluated at weeks 1,2,3,4,8,12,16 and 26. Biochemical markers for bone and cartilage degradation were measured in urine/blood.

Interventions

DRUGInjection of Hyaluronan or Saline

Sponsors

Glostrup University Hospital, Copenhagen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients, men/women age \> 60 years with clinical, * Radiological and possible arthroscopical verified knee osteoarthritis. * Knee pain on the day of examination scoring more than 20 mm on a visual analogue scale (VAS) at baseline.

Exclusion criteria

* Age below 60 * Unconsciousness * Psychosis * Demens * Ingestion of drugs that may influence the results of the clinical examinations * Inflammatory diseases of the joints * Rheumatoid arthritis or other inflammatory arthritis as diagnosed by American College of Rheumatology criteria * Contraindication to hyalgan treatment * Previous intraarticular fracture of a knee joint * Infection or skin disease located at the place of injection and invasive procedures done to the knee joint within previous two months inclusive intra-articular injections of steroids. * Any other condition that might interfere with the efficacy assessment or completion of the trial.

Design outcomes

Primary

MeasureTime frame
Pain measured on a visual scale on movement (VAS-movement)
At rest (VAS-rest)
During the night (VAS-night)

Secondary

MeasureTime frame
The quadriceps circumference (cm), ability to bend (degrees flexion) and stretch (degrees extension) the knee joint
KOOS scores (knee injury and osteoarthritis outcome score)
Global assessment investigator
Global assessment patient
Daily consumption of analgetics
Cartilage and bone degradation markers

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026